Skip to main content
Ramy Mahmoud, MD, Preventive Medicine, Yardley, PA

RamyAlyMahmoudMDMPH

Preventive Medicine • Yardley, PA

Aerospace Medicine, Public Health & General Preventive Medicine

CEO, Optinose (NASDAQ: OPTN)

Join to view full profile

Dr. Mahmoud is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Mahmoud's full profile

Already have an account?

Education & Training

  • National Capital Consortium Public Health and General Preventive Medicine
    National Capital Consortium Public Health and General Preventive MedicineResidency, Public Health and General Preventive Medicine, 1992 - 1994
  • Harvard School of Public Health
    Harvard School of Public HealthMPH, Health Policy & Management, 1992 - 1993
  • Harvard Medical School
    Harvard Medical SchoolFellowship, Clinical Effectiveness, 1992 - 1992
  • United States Army School of Aviation Medicine
    United States Army School of Aviation MedicineFS, 1991 - 1991
  • National Capital Consortium
    National Capital ConsortiumResidency, Internal Medicine, 1987 - 1990
  • University of Miami Leonard M. Miller School of Medicine
    University of Miami Leonard M. Miller School of MedicineClass of 1987

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 1997 - 2024
  • FL State Medical License
    FL State Medical License 1990 - 2000
  • VA State Medical License
    VA State Medical License 1990 - 1994
  • LA State Medical License
    LA State Medical License 1987 - 1990
  • American Board of Internal Medicine Internal Medicine
  • American Board of Preventive Medicine Public Health & General Preventive Medicine

Publications & Presentations

PubMed

Press Mentions

  • Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCE
    Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCEMay 4th, 2023
  • Optinose Submits Supplemental New Drug Application for XHANCE Label Expansion
    Optinose Submits Supplemental New Drug Application for XHANCE Label ExpansionFebruary 21st, 2023
  • Investors Gain a Breath of Fresh Air from Ph. 3 CS Trial Results
    Investors Gain a Breath of Fresh Air from Ph. 3 CS Trial ResultsJune 14th, 2022
  • Join now to see all

Professional Memberships

Dr. Ramy Mahmoud, Dr. Ramy Mahmoud, MD, Dr. R Mahmoud, Dr. Ramy Aly Mahmoud